Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

MLA

Chavez, Julio C., et al. “Results of a Phase II Study of Lenalidomide and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia.” Leukemia Research, vol. 47, Aug. 2016, pp. 78–83. EBSCOhost, https://doi.org/10.1016/j.leukres.2016.05.012.

APA

Chavez, J. C., Piris-Villaespesa, M., Dalia, S., Powers, J., Turba, E., Nodzon, L., Komrokji, R., Sokol, L., Locke, F. L., Lancet, J., Sotomayor, E. M., Kharfan-Dabaja, M. A., & Pinilla-Ibarz, J. (2016). Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research, 47, 78–83. https://doi.org/10.1016/j.leukres.2016.05.012

Chicago

Chavez, Julio C, Miguel Piris-Villaespesa, Samir Dalia, John Powers, Elyce Turba, Lisa Nodzon, Rami Komrokji, et al. 2016. “Results of a Phase II Study of Lenalidomide and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia.” Leukemia Research 47 (August): 78–83. doi:10.1016/j.leukres.2016.05.012.